Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Meta-Analysis Links Diabetes to Increased Blood Cancer Risk

By LabMedica International staff writers
Posted on 21 Jun 2012
According to a new, worldwide meta-analysis, patients with type 2 diabetes have a significantly increased risk of developing certain types of blood cancers.

A collaborative study led by researchers at The Miriam Hospital (Providence, RI, USA) analyzed 26 (13 case-control and 13 cohort) published observational studies that had evaluated the association between diabetes mellitus type 2 and the incidence of lymphoma, leukemia, and myeloma. More...
The meta-analysis included more than 17,000 cases of type 2 diabetes and blood cancer worldwide. The researchers concluded that patients with type 2 diabetes have about 20% increased risk of developing leukemia, myeloma, and non-Hodgkin lymphoma, as well as a subtype of non-Hodgkin lymphoma known as peripheral T-cell lymphoma. They did not find any associations with Hodgkin lymphoma. The findings suggest type 2 diabetes could be associated with approximately 5% of all incidents of leukemia, myeloma, and non-Hodgkin lymphoma.

The researchers also found that the risk of lymphoma, leukemia, and myeloma appears to differ depending on the geographic region of the original report. For example, the risk of non-Hodgkin lymphoma was higher in Asia and Europe, while there was an increased leukemia risk in the United States and Asia.

“When you consider that [millions of people have type 2 diabetes and that millions more are still likely to develop it], a 20% increased risk of blood cancer is quite significant,” noted lead author Jorge Castillo, MD, a hematologist-oncologist with The Miriam Hospital. He added, “It’s important to remember that type 2 diabetes can, to some degree, be prevented and controlled through lifestyle modification, such as diet and exercise; so by preventing the onset of type 2 diabetes, we could also prevent blood cancer.” Dr. Castillo and colleagues suggested that, in addition to studying antidiabetic therapy, future research should focus particularly on evaluating roles of behavioral factors such as obesity, physical activity, dietary habits, and smoking, which have been linked to both diabetes and cancer.

The findings, published online May 24, 2012, in the American Society of Hematology journal Blood, add to the growing evidence base linking diabetes and certain types of cancer.

Related Links:

The Miriam Hospital



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers identified 157 metabolites linked to BBB damage, including 25 that appeared in at least two independent studies (Image Credit: Adobe Stock)

Blood Metabolite Patterns May Enable Early Detection of Blood-Brain Barrier Injury

Early injury to the blood-brain barrier (BBB) can precede many neurological disorders but remains difficult to detect noninvasively. Laboratory markers that identify barrier dysfunction before symptoms... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.